狄诺塞麦用法以及用量

It is the first approved monoclonal antibody specifically targeting RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. Human RANKL mRNA is mainly found in bones, bone marrow and lymphoid tissues. Its main function in bones is to stimulate the differentiation and activity of osteoclasts and inhibit the apoptosis of osteoclasts. Denosumab has a high affinity with RANKL, preventing RANK ligand from activating RANK on the surface of osteoclasts, inhibiting osteoclast activation and development, reducing bone resorption, increasing bone density and bone strength of both cortical bone and trabecular bone, promoting bone reconstruction, and reducing the incidence of vertebral, non-vertebral and hip fractures in postmenopausal osteoporotic women.

To achieve the therapeutic effect of denosumab, you must first understand the medication method and use it as prescribed. What is the usage and dosage of denosumab?

Denosumab requires subcutaneous injection (upper arm, upper thigh, or abdomen) of 120 mg every 4 weeks, along with calcium or vitamin D infusion to prevent hypocalcemia.

Unresectable or surgical resection of giant cell tumor of bone in adults or bone-mature adolescents may cause serious complications: subcutaneous injection (upper arm, upper thigh or abdomen), 120 mg, once every 4 weeks. In the first month of treatment, 120 mg will be added on the 8th and 15th days respectively, and calcium or vitamin D will be infused to prevent hypocalcemia. Hypercalcemia of malignant tumors: subcutaneous injection, 120 mg, once every 4 weeks. During the first month of treatment, add 120 mg on the 8th and 15th days respectively.

Hypocalcemia must be corrected before starting treatment. For patients who are prone to hypocalcemia and mineral metabolism imbalance (such as those with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malnutrition, small bowel resection, severe renal insufficiency), clinical monitoring of creatinine and mineral levels is required, and such patients should be instructed to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D. Pregnant women and children should use it with caution. Denosumab should not be used in patients with allergies or hypocalcemia.